Questions, Answered as Far as the Evidence Reaches

What does retatrutide do?

In clinical trials, retatrutide reduced body weight and improved blood-sugar control. In a 48-week Phase 2 trial in 338 adults with obesity, the 12 mg once-weekly group had a mean body-weight change of -24.2% against -2.1% on placebo ^[4]. In a 36-week Phase 2 trial in 281 adults with type 2 diabetes, the same dose lowered HbA1c by 2.02 percentage points at 24 weeks and reduced body weight by 16.94% at 36 weeks ^[5]. A separate substudy in people with obesity and metabolic dysfunction-associated steatotic liver disease reported an -82.4% relative reduction in liver fat at 24 weeks at the highest dose, with 86% of that group reaching normal liver fat ^[3].

Those are trial results in supervised participants, not approved uses. Retatrutide has no approved indication anywhere.

How does retatrutide work?

Retatrutide is a single molecule that activates three receptors: GLP-1, GIP and glucagon. Cryo-electron microscopy has resolved all three receptor complexes and characterised the engagement, reporting roughly 8.9-fold greater potency than native GIP at the GIP receptor but 0.3-fold and 0.4-fold potency relative to the endogenous hormones at the glucagon and GLP-1 receptors ^[2].

Functionally, the GLP-1 and GIP arms suppress appetite and support glucose-dependent insulin secretion, while the glucagon arm is proposed to add energy expenditure and lipid mobilisation — reducing intake and increasing output at the same time ^[1]. A post-hoc metabolomic analysis found that changes in a fatty-acid-oxidation cluster mediated 23.2% of the weight-reduction response in participants without type 2 diabetes, which supports part of that account rather than all of it ^[7].

How to reconstitute retatrutide?

peptideradar does not publish reconstitution, handling or preparation instructions for any compound, and this is a deliberate editorial position rather than an oversight.

The reason is straightforward. Retatrutide is an investigational drug with no approved formulation, no approved concentration and no approved route ^[1]. In the trials cited on this site it was administered as a manufactured, quality-controlled study product under clinical supervision. Material sold outside that channel has no verified identity, concentration or sterility, so there is no correct set of preparation instructions to give — the arithmetic of a reconstitution guide implies a known quantity of a known substance, and in a gray-market vial neither is known.

Anyone searching this question is describing an unsupervised injection of an unapproved drug of unverified content. The relevant answer from the literature is a risk profile, not a procedure: contamination, endotoxin exposure and dosing error are all documented concerns with unregulated injectable peptides.

Is retatrutide FDA approved?

No. Retatrutide is investigational and is in Phase 3 clinical trials with Eli Lilly. It has not been approved by the FDA or by any other regulator as of 2026, and it has no approved indication, formulation or dosing ^[1].

Every efficacy and safety figure quoted for retatrutide — here or anywhere — comes from clinical trials rather than from approved labelling. The Phase 3 programme has not reported, and dedicated cardiovascular and kidney outcome trials are ongoing ^[1]. Sale of research-labelled retatrutide sits outside the regulated channel entirely, and US regulators have issued warning letters to vendors citing federal food-and-drug law violations.

What does the MOTS-c peptide do?

In cells and animals, MOTS-c activates AMPK — a cellular fuel sensor — by inhibiting the folate cycle and de novo purine biosynthesis, which raises AICAR. Downstream effects reported in that work include improved glucose handling and insulin sensitivity, primarily in skeletal muscle ^[10]. Under metabolic stress the peptide also moves from the mitochondrion into the nucleus and alters nuclear gene expression in an AMPK-dependent manner, including antioxidant-response genes via NRF2 ^[12]. A 2024 study identified casein kinase 2 as a direct binding target and linked tissue-specific CK2 modulation to muscle glucose uptake and prevention of muscle atrophy ^[8].

In mice, exogenous MOTS-c improved treadmill running capacity, grip strength and gait, including in animals aged 22 to 23.5 months ^[11].

What MOTS-c does in people who are given it is unknown. No interventional human trial has been published.

What are the negative side effects of MOTS-c?

There is no reliable answer to this question, and that is the answer worth having.

Side effects are catalogued by giving a compound to people under controlled observation and recording what happens. No such study of MOTS-c has been published. There is no controlled human safety trial, no measured human pharmacokinetics, and no established human dose — so there is no adverse-event profile to report, favourable or otherwise ^[9][10].

An empty side-effect list should be read as missing data rather than as a clean bill of health. Two further points are documented: material sold as research-grade MOTS-c is not manufactured to pharmaceutical standards, so identity, purity and sterility vary by supplier; and effects appear not to be uniform across populations, with a pro-diabetogenic mitochondrial variant (m.1382A>C) and ancestry-dependent exercise responses both reported in the literature.

Is MOTS-c legal to buy?

MOTS-c is sold by chemical suppliers as a research chemical for laboratory use only. It is not approved by the FDA for human use, it has no approved indication or formulation, and it is not a dietary supplement. That status is what allows it to be listed for sale as laboratory material, and it is also what places any human use outside every regulatory framework that exists to verify what is in a vial.

Two separate points are often conflated here. First, research-labelled sale is not an approval, and it carries no guarantee of identity, purity or sterility. Second, anti-doping authorities treat MOTS-c as a prohibited peptide in elite sport under hormone-and-metabolic-modulator categories, so a tested athlete faces sanctions regardless of how the material was purchased. peptideradar does not link to, recommend or evaluate suppliers of any compound.

How often do you inject MOTS-c?

No validated human dosing schedule exists, and this site will not supply one.

The published record contains no measured human half-life, bioavailability or dose-response relationship for MOTS-c ^[10]. Animal studies use regimens chosen for the species and model in question, and rodent dosing cannot be scaled to people by body weight or by any other rule of thumb — species differences in clearance, distribution and receptor biology make that arithmetic meaningless.

Any frequency circulating online as a MOTS-c protocol therefore has no measured basis in the published literature. It is a convention that spread through communities, not a finding. Where a protocol is presented with the confidence of a prescription, the confidence is the invented part.

What is KPV peptide?

KPV is a tripeptide — lysine, proline and valine — corresponding to residues 11 to 13, the C-terminal end, of alpha-melanocyte-stimulating hormone. Its molecular formula is C16H30N4O4, and it appears in the literature as Lys-Pro-Val or alpha-MSH(11-13).

Its distinguishing property is that it retains the parent hormone's anti-inflammatory activity while lacking its pigmentary action ^[17]. In research models it is imported into intestinal epithelial cells by the di- and tripeptide transporter PepT1, which is upregulated in inflamed tissue, and it suppresses NF-kB and MAP-kinase inflammatory signalling once inside ^[15].

KPV is not an approved drug or dietary supplement in any major jurisdiction; it is supplied for laboratory research use only.

What does KPV peptide do?

In laboratory models, KPV reduces inflammation. At nanomolar concentrations in human intestinal epithelial cell lines and in Jurkat T cells it lowers NF-kB and MAP-kinase activation and reduces secretion of pro-inflammatory cytokines including IL-1beta and TNF-alpha ^[15]. In mice with chemically induced colitis, orally administered KPV reduced disease severity in both DSS and TNBS models ^[15], and a separate study reported earlier recovery, greater body-weight regain, reduced colonic inflammatory infiltrate and lower myeloperoxidase activity — with the effect preserved in MC1R-deficient animals, indicating it does not require the melanocortin-1 receptor ^[16].

In people, KPV has not been shown to do anything, because it has not been tested. No human clinical trial of KPV has been published.

What is KPV peptide used for?

In published research, KPV is used almost entirely as an experimental anti-inflammatory agent in models of intestinal inflammation. The four experimental sources behind this site all sit in that area: PepT1-mediated uptake and inflammatory signalling in cells and colitis mice ^[15]; a murine inflammatory-bowel-disease model ^[16]; orally administered hyaluronic-acid-functionalised nanoparticles in a chitosan/alginate hydrogel ^[14]; and a 2024 PepT1-targeted nanodrug co-assembling KPV with the immunosuppressant FK506 for acute and chronic colitis ^[13]. A review places the wider alpha-MSH tripeptide family across models of fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic and organ injury ^[17].

Note what that list is: research uses, in animals and cell culture. KPV has no approved therapeutic use, and it is not used in clinical practice anywhere.

What is KPV peptide good for?

Judged against the published evidence, KPV is good for one thing with confidence: studying how a small melanocortin fragment suppresses inflammatory signalling in epithelial tissue. The mechanism is consistent, reproduced by independent groups, and biologically interesting ^[15][16][17].

What it has not been shown to be good for is any human condition. There is no published human clinical trial, no established human dose and no human safety data. The marketing of KPV for gut health, skin and general anti-inflammatory use runs ahead of a record that is mechanistic and preclinical rather than clinical.

A further practical limit sits underneath the claims: free KPV is a small, peptidase-labile tripeptide, and much of the recent literature is formulation work aimed at keeping it intact long enough to act ^[13][14]. A compound whose delivery problem is still an open research question is not a compound with a settled use.